Research programme: anti-sperm antibody - Epicyte

Drug Profile

Research programme: anti-sperm antibody - Epicyte

Alternative Names: Anti-sperm antibody research programme - Epicyte

Latest Information Update: 02 Feb 2015

Price : $50

At a glance

  • Originator Epicyte Pharmaceutical; ReProtect LLC
  • Developer Dow Chemical; Epicyte Pharmaceutical; ReProtect
  • Class Antibodies; Spermicidal contraceptives
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Contraception

Most Recent Events

  • 02 Feb 2015 Discontinued - Preclinical for Contraception in USA (Topical)
  • 11 Mar 2003 No development reported - Preclinical for Contraception in USA (Topical)
  • 08 Nov 2000 Preclinical development for Contraception in USA (Topical)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top